Literature DB >> 9061191

Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation.

D L Boger1, R M Garbaccio.   

Abstract

A number of indirect observations are summarized that suggest the rate acceleration for the CC-1065 and duocarmycin. DNA alkylation reaction is derived in part from a DNA binding-induced conformational change in the agents which substantially increases their inherent reactivity. This ground-state destabilization of the agent, which we suggest results from a binding-induced twist in the linking N2 amide and requires a rigid extended N2 amide substituent, disrupts the vinylogous amide stabilization and activates the agents for DNA alkylation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061191     DOI: 10.1016/s0968-0896(96)00238-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  31 in total

1.  Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]oxazolo[2,3-e]indol-4-one-6-carboxylate (COI) alkylation subunit.

Authors:  Kristopher E Boyle; Karen S MacMillan; David A Ellis; James P Lajiness; William M Robertson; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-02-02       Impact factor: 2.823

2.  Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity.

Authors:  Mark S Tichenor; Karen S MacMillan; John D Trzupek; Thomas J Rayl; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-08-11       Impact factor: 15.419

Review 3.  Enzymatic chemistry of cyclopropane, epoxide, and aziridine biosynthesis.

Authors:  Christopher J Thibodeaux; Wei-chen Chang; Hung-wen Liu
Journal:  Chem Rev       Date:  2011-10-21       Impact factor: 60.622

4.  The Mechanism of Action of (-)-Lomaiviticin A.

Authors:  Seth B Herzon
Journal:  Acc Chem Res       Date:  2017-09-28       Impact factor: 22.384

5.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

6.  Structural basis for DNA cleavage by the potent antiproliferative agent (-)-lomaiviticin A.

Authors:  Christina M Woo; Zhenwu Li; Eric K Paulson; Seth B Herzon
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

7.  Synthesis and evaluation of a series of C5'-substituted duocarmycin SA analogs.

Authors:  William M Robertson; David B Kastrinsky; Inkyu Hwang; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-03-25       Impact factor: 2.823

Review 8.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

9.  Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.

Authors:  Mark S Tichenor; John D Trzupek; David B Kastrinsky; Futoshi Shiga; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2006-12-13       Impact factor: 15.419

10.  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.

Authors:  Wei Jin; John D Trzupek; Thomas J Rayl; Melinda A Broward; George A Vielhauer; Scott J Weir; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-11-17       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.